On April 26, at the 2024 Suzhou Global Investment Promotion Conference, Gong Xuejie, senior director of Kexing Holdings Biotechnology Co., Ltd. (hereinafter referred to as “SINOVAC”) and executive deputy general manager of Xingmeng Biomedical (Suzhou) Co., Ltd. (hereinafter referred to as “Xingmeng Biotech”), signed a contract with Suzhou Industrial Park for the “Xingmeng Antibody R&D and Manufacturing Base” project on behalf of the company. Previously, SINOVAC had completed its investment in Xingmeng Biotech. According to reports, zemelovir mazorevir, the first domestic anti-rabies cocktail monoclonal antibody combination developed independently by Xingmeng Biotech, is expected to be marketed domestically within the year, and will submit a biological product license application to the US FDA in the near future.